Colin D. Weekes

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• A phase II study of FOLFIRINOX (FFX) combined with the glycogen synthase kinase-3beta (GSK-3β) inhibitor elraglusib (ELRA) and the transforming growth factor beta (TGFβ) inhibitor losartan (LOS) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

  Journal of Clinical Oncology · 2026-05-27

• Avatrombopag for chemotherapy-induced thrombocytopenia in gastrointestinal malignancies (ACT-GI): A multicenter, U.S., randomized, double-blind, placebo-controlled clinical trial.

  Journal of Clinical Oncology · 2026-05-27

• Feasibility and acceptability of an electronic decision aid for genetic testing in ovarian and pancreatic cancer patients

  Research Connections · 2026-03-19

• Disparities in the diagnosis and management of exocrine pancreatic insufficiency in resectable vs metastatic pancreatic cancer

  The Oncologist · 2026-03-09

• Supplementary Data2 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer

  2026-03-02

• Supplementary Data1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer

  2026-03-02

• Data from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer

  2026-03-02

• Table S1 - Representation1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer

  2026-03-02

• DEG table1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer

  2026-03-02

• Tolerability and outcomes after neoadjuvant and definitive radiation of elderly patients with localized pancreatic cancer.

  Journal of Clinical Oncology · 2026-01-10

• Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer

  Clinical Cancer Research · 2025-12-09

• Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study

  The Oncologist · 2025-09-16

• Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer

  JCO Precision Oncology · 2025-09-01 · 3 citations

• Phase IB/II Study of Trifluridine/Tipiracil Hydrochloride (FTD/TPI) Plus Radiation Therapy for the Treatment of the Liver in Patients with Hepatic Metastases from Colorectal and Pancreatic Cancer

  International Journal of Radiation Oncology*Biology*Physics · 2025-09-01

• Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results

  Nature Medicine · 2025-08-11 · 44 citations

• Phase 1/2 study of the trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy or combination therapy in gastrointestinal cancers: LIGHTBEAM-02A.

  Journal of Clinical Oncology · 2025-01-27 · 2 citations

• Supplementary Figure S2 from A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid TumorsPreprint

  2025-01-06

• Data from A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid TumorsPreprint

  2025-01-06

• Supplementary Table S1 from A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors

  2025-01-06

• Supplementary Figure S3 from A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid TumorsPreprint

  2025-01-06